Global pharma major, Lupin Limited (Lupin) announced that it has signed a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing and selling of Lilly’s drug Baricitinib in India. Lilly has received permission from Central Drugs Standard Control Organization (CDSCO), Ministry of Health, for restricted emergency use of Baricitinib in…
Lupin Limited (Lupin), global pharmaceutical company, announced the appointment of Mark D. McDade as an Independent Director effective January 28, 2021. McDade is the co-Founder and Partner at Qiming Venture Partners, USA where he led several high-value investments in biotherapeutics, including cell and gene therapy and digital health. With a career spanning over 37 years,…
Pharma major Lupin Limited announced the launch of its Favipiravir in India under the brand name Covihalt for the treatment of mild to moderate COVID-19. Favipiravir has received authorization from the Drug Controller General of India (DCGI) for emergency use, the company mentioned in its press note. Lupin’s Covihalt dosage strength has been developed keeping…
Lupin Limited, an innovation-led transnational pharmaceutical company headquartered in Mumbai, announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) after closure of the inspection for its Vizag facility. The inspection for the API facility was conducted by the U.S. FDA between January 13, 2020 and…
Pharma major Lupin Limited announced the successful close out of the inspection carried out by the Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory agency of the United Kingdom (UK), at its three manufacturing units in Pithampur (India). The inspection for the three units at Pithampur (Unit I, Unit II and Unit III) was…
Lupin Limited the transnational pharmaceutical company based in Mumbai, announced the exit of the company’s Chief Financial Officer, Ramesh Swaminathan on Tuesday in a statement to the exchanges. “We wish to inform that Ramesh Swaminathan, Chief Financial Officer of the Company has decided to pursue other responsibilities outside the pharmaceutical industry and will be leaving the organization…
Lupin board of directors has approved the appointment of Vinita Gupta as Chief Executive Officer and Nilesh D. Gupta as Managing Director from September 2013. Vinita and Nilesh are children of Dr. Desh Bandhu Gupta, Lupin’s Founder and Chairman. Kamal K. Sharma, present the company’s Managing Director would move up as Vice-Chairman. Vinita Gupta, has…